Mostrar el registro sencillo del ítem

Artículo

dc.creatorAlba Jiménez, Gonzaloes
dc.creatorMartínez, Raqueles
dc.creatorPostigo Corrales, Fátimaes
dc.creatorLópez Enríquez, Soledades
dc.creatorSanta-María Pérez, Consueloes
dc.creatorJiménez Carrasco, Juanes
dc.creatorCahuana Macedo, Gladys Margotes
dc.creatorSoria Escoms, Bernates
dc.creatorBedoya Bergua, Francisco Javieres
dc.creatorTejedo Huamán, Juan Rigobertoes
dc.date.accessioned2020-12-15T11:15:11Z
dc.date.available2020-12-15T11:15:11Z
dc.date.issued2020
dc.identifier.citationAlba Jiménez, G., Martínez, R., Postigo Corrales, F., López Enríquez, ., Santa-María Pérez, C., Jiménez Carrasco, J.,...,Tejedo Huamán, J.R. (2020). AICAR Stimulates the Pluripotency Transcriptional Complex in Embryonic Stem Cells Mediated by PI3K, GSK3β, and β-Catenin. ACS Omega, 5 (32), 20270-20282.
dc.identifier.issn2470-1343es
dc.identifier.urihttps://hdl.handle.net/11441/103229
dc.description.abstractPluripotent stem cells maintain the property of self-renewal and differentiate into all cell types under clear environments. Though the gene regulatory mechanism for pluripotency has been investigated in recent years, it is still not completely understood. Here, we show several signaling pathways involved in the maintenance of pluripotency. To investigate whether AMPK is involved in maintaining the pluripotency in mouse embryonic stem cells (mESCs) and elucidating the possible molecular mechanisms, implicated D3 and R1/E mESC lines were used in this study. Cells were cultured in the absence or presence of LIF and treated with 1 mM and 0.5 mM 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR), 2 mM metformin, compound C, and the PI3K inhibitor LY294002 for 24, 72, and 120 h. The levels of Nanog, Oct3/4, and REX1 and Brachyury, Notch2, and Gata4 mRNAs and Nanog or OCT3/4 protein levels were analyzed. Alkaline phosphatase and the cellular cycle were determined. The pGSK3β, GSK3β, p-β-catenin, and β-catenin protein levels were also investigated. We found that AMPK activators such as AICAR and metformin increase mRNA expression of pluripotency markers and decrease mRNA expression of differentiation markers in R1/E and D3 ES cells. AICAR increases phosphatase activity and arrests the cellular cycle in the G1 phase in these cells. We describe that AICAR effects were mediated by AMPK activation using a chemical inhibitor or by silencing this gene. AICAR effects were also mediated by PI3K, GSK3β, and β-catenin in R1/E ES cells. According to our findings, we provide a mechanism by which AICAR increases and maintains a pluripotency state through enhanced Nanog expression, involving AMPK/PI3K and p-GSK3β Ser21/9 pathways backing up the AICAR function as a potential target for this drug controlling pluripotency. The highlights of this study are that AICAR (5-aminoimidazole-4-carboxamied-1-b-riboside), an AMP protein kinase (AMPK) activator, blocks the ESC differentiation and AMPK is a key enzyme for pluripotency and shows valuable data to clarify the molecular pluripotency mechanism.es
dc.description.sponsorshipEspaña Ministerio de Economía y Competitividad Proyect, No. IPT-2011-1615-900000es
dc.description.sponsorshipEspaña Instituto de Salud Carlos III, No. TERCEL RD06/0010/0025es
dc.description.sponsorshipEspaña Consejería de Salud Junta de Andalucía No. PI-0105- 2010es
dc.description.sponsorshipEspaña Consejería de Economía Innovación Ciencia y Empleo - Junta de Andalucia No. CTS-7127/ 2011es
dc.formatapplication/pdfes
dc.format.extent12 p.es
dc.language.isoenges
dc.publisherAmerican Chemical Societyes
dc.relation.ispartofACS Omega, 5 (32), 20270-20282.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleAICAR Stimulates the Pluripotency Transcriptional Complex in Embryonic Stem Cells Mediated by PI3K, GSK3β, and β-Catenines
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.projectIDIPT-2011-1615-900000es
dc.relation.projectIDNo. TERCEL RD06/0010/0025es
dc.relation.projectIDNo. PI-0105- 2010es
dc.relation.projectIDNo. CTS-7127/ 2011es
dc.relation.publisherversionhttps://doi.org/10.1021/acsomega.0c02137es
dc.identifier.doi10.1021/acsomega.0c02137es
dc.journaltitleACS Omegaes
dc.publication.volumen5es
dc.publication.issue32es
dc.publication.initialPage20270es
dc.publication.endPage20282es
dc.contributor.funderMinisterio de Economía y Competitividad (MINECO). Españaes
dc.contributor.funderInstituto de Salud Carlos IIIes
dc.contributor.funderJunta de Andalucíaes

FicherosTamañoFormatoVerDescripción
pubacsomega.0c02137.pdf5.888MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional